Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 120

1.

Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.

Sugimoto Y, Sawant DB, Fisk HA, Mao L, Li C, Chettiar S, Li PK, Darby MV, Brueggemeier RW.

Bioorg Med Chem. 2017 Apr 1;25(7):2156-2166. doi: 10.1016/j.bmc.2017.02.030. Epub 2017 Feb 16.

PMID:
28259529
2.

Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.

Eloy JO, Petrilli R, Brueggemeier RW, Marchetti JM, Lee RJ.

Anticancer Agents Med Chem. 2017;17(1):48-56.

3.

Oncolytic potential of a novel KGFR tyrosine kinase inhibitor using a KGFR-selective breast cancer xenograft model.

Kesinger JW, Mehta M, Lerner MR, Brackett DJ, Brueggemeier RW, Li PK, Pento JT.

Anticancer Res. 2015 Jan;35(1):47-52.

PMID:
25550534
4.

Maintaining pharmacy education's research focus as the academy expands.

Bauman JL, Ascione FJ, Brueggemeier RW, Letendre DE, Roberts JC, Speedie MK, Svensson CK.

Am J Pharm Educ. 2012 Oct 12;76(8):144. doi: 10.5688/ajpe768144. No abstract available.

5.

Are we producing innovators and leaders or change resisters and followers?

Svensson CK, Ascione FJ, Bauman JL, Brueggemeier RW, Letendre DE, Roberts JC, Speedie MK.

Am J Pharm Educ. 2012 Sep 10;76(7):124. doi: 10.5688/ajpe767124. No abstract available.

6.

Highly efficient cationic ethylphosphatidylcholine siRNA carrier for GFP suppression in modified breast cancer cells.

Tenchov B, Sugimoto Y, Koynova R, Brueggemeier RW, Lee RJ.

Anticancer Res. 2012 Jul;32(7):2563-6.

7.

Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer.

Piao L, Li H, Teng L, Yung BC, Sugimoto Y, Brueggemeier RW, Lee RJ.

Nanomedicine. 2013 Jan;9(1):122-9. doi: 10.1016/j.nano.2012.03.008. Epub 2012 Apr 26.

8.

Differential efficacy of DOTAP enantiomers for siRNA delivery in vitro.

Terp MC, Bauer F, Sugimoto Y, Yu B, Brueggemeier RW, Lee LJ, Lee RJ.

Int J Pharm. 2012 Jul 1;430(1-2):328-34. doi: 10.1016/j.ijpharm.2012.04.017. Epub 2012 Apr 15.

9.

The path forward: the future of graduate education in the pharmaceutical sciences: the report of the 2010-2011 Research and Graduate Affairs Committee.

Brueggemeier RW, Clark AM, Das SK, Forbes DS, Leff RD, Oie S, Sorofman BA, Thompson DF, Maine LL, Sagraves R.

Am J Pharm Educ. 2011 Dec 15;75(10):S13. doi: 10.5688/ajpe7510S13. No abstract available.

10.

SPANosomes as delivery vehicles for small interfering RNA (siRNA).

Zhou C, Mao Y, Sugimoto Y, Zhang Y, Kanthamneni N, Yu B, Brueggemeier RW, Lee LJ, Lee RJ.

Mol Pharm. 2012 Feb 6;9(2):201-10. doi: 10.1021/mp200426h. Epub 2011 Dec 29.

11.

Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer.

Díaz-Cruz ES, Sugimoto Y, Gallicano GI, Brueggemeier RW, Furth PA.

Cancer Res. 2011 Aug 15;71(16):5477-87. doi: 10.1158/0008-5472.CAN-10-4652.

12.

Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.

Lustberg MB, Povoski SP, Zhao W, Ziegler RM, Sugimoto Y, Ruppert AS, Lehman AM, Shiels DR, Mrozek E, Ramaswamy B, Layman RM, Brueggemeier RW, Shapiro CL.

Clin Breast Cancer. 2011 Aug;11(4):221-7. doi: 10.1016/j.clbc.2011.03.022. Epub 2011 May 19.

13.

Reconsidering the length of program accreditation.

Svensson CK, Speedie MK, Roberts JC, Letendre DE, Brueggemeier RW, Bauman JL, Ascione FJ.

Am J Pharm Educ. 2011 Feb 10;75(1):6. No abstract available.

14.

Influence of novel KGFR tyrosine kinase inhibitors on KGF-mediated proliferation of breast cancer.

Mehta M, Kesinger JW, Zang XP, Lerner ML, Brackett DJ, Brueggemeier RW, Li PK, Pento JT.

Anticancer Res. 2010 Dec;30(12):4883-9.

PMID:
21187466
15.

Isolation and Characterization of Aromatase Inhibitors from Brassaiopsis glomerulata (Araliaceae).

Balunas MJ, Su B, Riswan S, Fong HH, Brueggemeier RW, Pezzuto JM, Kinghorn AD.

Phytochem Lett. 2009 Feb 19;2(1):29-33.

16.

Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells.

Zheng Y, Yu B, Weecharangsan W, Piao L, Darby M, Mao Y, Koynova R, Yang X, Li H, Xu S, Lee LJ, Sugimoto Y, Brueggemeier RW, Lee RJ.

Int J Pharm. 2010 May 10;390(2):234-41. doi: 10.1016/j.ijpharm.2010.02.008. Epub 2010 Feb 13.

17.

Selective regulation of aromatase expression for drug discovery.

Brueggemeier RW, Su B, Darby MV, Sugimoto Y.

J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):207-10. doi: 10.1016/j.jsbmb.2009.11.009. Epub 2009 Dec 1.

18.

Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?

Miller WR, Bartlett J, Brodie AM, Brueggemeier RW, di Salle E, Lønning PE, Llombart A, Maass N, Maudelonde T, Sasano H, Goss PE.

Oncologist. 2008 Aug;13(8):829-37. doi: 10.1634/theoncologist.2008-0055. Epub 2008 Aug 11. Review.

19.

Natural products as aromatase inhibitors.

Balunas MJ, Su B, Brueggemeier RW, Kinghorn AD.

Anticancer Agents Med Chem. 2008 Aug;8(6):646-82. Review.

20.

Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity.

Balunas MJ, Su B, Brueggemeier RW, Kinghorn AD.

J Nat Prod. 2008 Jul;71(7):1161-6. doi: 10.1021/np8000255. Epub 2008 Jun 18.

Supplemental Content

Loading ...
Support Center